1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable

Technology appraisal guidance [TA787] Published: 27 April 2022

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Tools and resources

Tools to help you put the guidance into practice.

Resource impact

  • Resource impact template Excel 1.32 MB 27 April 2022  
  • Resource impact statement  

Guidance into practice

  • About the Into practice guide  
  • Practical steps to improving the quality of care and services using NICE guidance